Moffitt Cancer Center
Tampa, FL USA

Our News on Newswise

Moffitt Cancer Center Receives $3.6 Million Grant to Study E-Cigarettes

Moffitt Cancer Center received a $3.6 million grant from the National Institutes of Health to study the use of electronic cigarettes, or e-cigarettes, over the next five years.
30-Jun-2015 9:00 AM EDT

Researchers Discover Mechanism Leading to BRAF Inhibitor Resistance in Melanoma Patients

The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining cells adapt to...
19-Jun-2015 4:00 PM EDT

Latina Women Undergoing Chemotherapy for Breast Cancer Need More Culturally Relevant, Language-Specific Stress Management Tools

Moffitt Cancer Center researchers, along with collaborators at the University of South Florida, recently published a study about the attitudes and cultural perspectives of Latinas undergoing chemotherapy for breast cancer. The article also discusses...
19-Jun-2015 3:00 PM EDT

MEDI4736 Combined with Tremelimumab Results in Acceptable Toxicity, Clinical Activity in Non-Small Cell Lung Cancer Patients

Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as...
28-May-2015 2:05 PM EDT

Component in Green Tea May Help Reduce Prostate Cancer in Men at High Risk

Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention – the use of agents to prevent...
28-May-2015 2:05 PM EDT

JAK2 Inhibitor Ruxolitinib has Minimal Toxicity, Promising Efficacy in Chronic Myelomonocytic Leukemia Patients

Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only...
28-May-2015 2:05 PM EDT

Nivolumab Treatment in Melanoma Patients has Manageable Safety Profile, Additional Immunomodulatory Agents Do Not Affect Response Rates

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at...
28-May-2015 2:05 PM EDT

Surgery Followed by Ipilimumab Treatment in Melanoma Patients Improves Survival

Melanoma is predicted to result in approximately 10,000 deaths in 2015. The majority of these deaths are due to advanced stage disease that has spread or metastasized to other sites. The prognosis for patients with metastatic melanoma remains poor,...
20-May-2015 10:00 AM EDT

Our Experts on Newswise

Our experts are coming soon...

Our YouTube Videos